Filip P. Janku
Expertise in
36
conditions

Dr. Filip P. Janku

Houston, TX
Expertise in
36
conditions
Specialties:Internal Medicine
26 Years of Experience
Expertise in
36
conditions
OverviewInsuranceLocationsClinical Research

Overview

Filip Janku is an Internal Medicine provider in Houston, Texas. Dr. Janku has been practicing medicine for over 26 years is highly rated in 36 conditions, according to our data. His top areas of expertise are Erdheim-Chester Disease, Gastrointestinal Stromal Tumor, Colorectal Cancer, Lung Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 278 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1999
Specialties
Internal Medicine
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

1515 Holcombe Blvd, Houston, TX 77030
713-792-6161

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: January 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: ASTX295
Study Phase: Phase 1/Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib Investigation of Pembrolizumab in Combination with Intratumoral Injection of Clostridium Novyi-NT in Patients with Treatment-Refractory Solid Tumors
A Phase Ib Investigation of Pembrolizumab in Combination with Intratumoral Injection of Clostridium Novyi-NT in Patients with Treatment-Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2024
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Clostridium Novyi-NT, Doxycycline
Study Phase: Phase 1
A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drug: HMPL-306
Study Phase: Phase 1
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
Enrollment Status: Terminated
Publish Date: May 03, 2024
Intervention Type: Drug
Study Drugs: SYNB1891, Atezolizumab
Study Phase: Phase 1
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab
A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Enrollment Status: Terminated
Publish Date: December 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: June 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drug: FF-10502-01
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease
Enrollment Status: Withdrawn
Publish Date: March 17, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies
A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies
A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 25, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies
A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 1
Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance
Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug, Biological, Other
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: November 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
Enrollment Status: Terminated
Publish Date: September 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 27 Less Clinical Trials

278 Total Publications

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
Journal: Cancer medicine
Published: April 05, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Paolo Strati
Internal Medicine
Expertise in
22
conditions
Dr. Paolo Strati
Internal Medicine

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paolo Strati is an Internal Medicine provider in Houston, Texas. Dr. Strati is highly rated in 22 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Expertise in
24
conditions
Dr. Salim S. Virani
Internal Medicine
Expertise in
24
conditions
Dr. Salim S. Virani
Internal Medicine
6565 Fannin St Ste B157, 
Houston, TX 
 (0.3 mi)
713-798-5800
Languages Spoken:
English

Salim Virani is an Internal Medicine provider in Houston, Texas. Dr. Virani is highly rated in 24 conditions, according to our data. His top areas of expertise are Atherosclerosis, High Cholesterol, Coronary Heart Disease, Coronary Artery Bypass Graft (CABG), and Percutaneous Coronary Intervention (PCI).

Expertise in
18
conditions
Dr. Dai Chihara
Internal Medicine
Expertise in
18
conditions
Dr. Dai Chihara
Internal Medicine

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dai Chihara is an Internal Medicine provider in Houston, Texas. Dr. Chihara is highly rated in 18 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile